Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 5, Pages 1253-1261Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mds622
Keywords
adenocarcinoma; gastric; hER2; immunohistochemistry; in situ hybridisation; oesophageal
Categories
Funding
- CRUK [C20023/A7217]
- Medical Research Council through the MRC Clinical Trials Unit
- Breakthrough Breast Cancer
- NHS
- Amgen
- Merck Serono
- Roche
- Sanofi Aventis
- MRC [MC_U122861327] Funding Source: UKRI
- Medical Research Council [MC_U122861327] Funding Source: researchfish
Ask authors/readers for more resources
Background: Perioperative epirubicin, cisplatin and fluorouracil (ECF) chemotherapy improves survival in operable oesophago-gastric cancer [Adjuvant Gastric Cancer Infusional Chemotherapy (MAGIC) trial HR 0.75 (0.6-0.93)]. HER2 amplification is reported to predict enhanced benefit from anthracyclines in breast cancer. We sought to define whether HER2 predicts benefit from ECF in oesophago-gastric cancer. Patients and methods: Diagnostic biopsies and/or resection specimens were collected from 415 of 503 MAGIC trial patients (82.5%). HER2 was evaluated by immunohistochemistry (IHC) and brightfield dual in situ hybridisation (BDISH) in tissue microarrays. The prognostic and predictive impact of HER2 status was investigated. Results: Concordance between HER2 over-expression (IHC3+) and amplification was 96%. Results of HER2 assessment in biopsy and resection specimens were concordant in 92.9% (145/156). HER2 positive rate (IHC3+, or IHC2+/BDISH positive) was 10.9% in the whole cohort and 10.4% in resection specimens. A further 4.0% of resections were IHC negative/BDISH positive. HER2 status was neither prognostic, nor (in pre-treatment biopsies) predicted enhanced benefit from chemotherapy [HER2 positive HR 0.74 (0.14-3.77); HER2 negative HR 0.58 (0.41-0.82), interaction P = 0.7]. However, the power of the predictive analysis was limited by the small number of HER2 positive pre-treatment biopsies. Conclusions: HER2 status is not an independent prognostic biomarker in early oesophago-gastric adenocarcinoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available